Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2011

View Archived Issues

Ampio and Daewoong enter urology drug agreement in South Korea

Diffusion tensor imaging detects cerebral anomalies in patients with Asperger's syndrome

Novel PET tracer may help guide development of fatty-acid amide hydrolase inhibitors

MedImmune presents new safety data on MEDI-573 in breast cancer

Synthesis and preclinical testing of novel histamine H3 receptor antagonists described

Repros completes enrollment in three ongoing Androxal trials

First-in-human study supports feasibility of intraoperative tumor-specific fluorescence imaging

Novel susceptibility gene for major depression identified

Randomized, double-blind trial assesses LY-2189265 as monotherapy for type 2 diabetes

BioLineRx reports preliminary first-in-human data on BL-1021

Nanobiotix's lead product enters clinic

Compugen validates immunomodulating fusion proteins in in vivo models of autoimmune diseases

GlaxoSmithKline discloses new fatty acid synthase inhibitors

Spanish research center prepares novel protein kinase inhibitors

Viamet Pharmaceuticals begins first-in-human trial of VT-1161

Novartis synthesizes novel cyclin-dependent kinase inhibitors

Rare Disease Therapeutics selects distributor for Anascorp

Avila Therapeutics advances phase Ib AVL-292 study

ProFibrix completes recruitment in two phase II Fibrocaps trials

Scientists at Medivation claim new neurotransmitter receptor modulators

Oncothyreon obtains license to anticancer agents from Sanford-Burnham Medical Research Institute

Arrien gathers financing to support advancement of small-molecule protein kinase inhibitors

Eisai enters collaboration with SFJ to conduct phase III E-7080 trials

Thrasos Innovation advances THR-184 to clinic

Astellas Pharma set to launch Betanis in Japan

Vibativ approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...